APA (7th ed.) Citation

Conteduca, V., Scarpi, E., Wetterskog, D., Brighi, N., Schepisi, G., Romanel, A., . . . De Giorgi, U. (2021). 583P Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide. Annals of Oncology, 32, S633. https://doi.org/10.1016/j.annonc.2021.08.1096

Chicago Style (17th ed.) Citation

Conteduca, V., et al. "583P Baseline Plasma Tumour DNA (ptDNA) Correlates with PSA Kinetics in Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide." Annals of Oncology 32 (2021): S633. https://doi.org/10.1016/j.annonc.2021.08.1096.

MLA (9th ed.) Citation

Conteduca, V., et al. "583P Baseline Plasma Tumour DNA (ptDNA) Correlates with PSA Kinetics in Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide." Annals of Oncology, vol. 32, 2021, p. S633, https://doi.org/10.1016/j.annonc.2021.08.1096.